Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594418615> ?p ?o ?g. }
- W2594418615 endingPage "69" @default.
- W2594418615 startingPage "60" @default.
- W2594418615 abstract "The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options.We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU.This prospective parallel group controlled study included 70 CIndU and 66 CSU patients. The same treatment algorithm recommended by the European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) was implemented to both CSU and CIndU patients. Treatment responses of the groups were evaluated with urticaria control test (UCT) and dermatology life quality questionnaire (DLQI) scores at the 0, 4, 8, 12 and 24th weeks for CIndU and 0, 4, 12 and 24 weeks for CSU.Fourteen patients (20,9%) with CIndU and 25 (37,9%) with CSU responded to standard doses of H1-AHs which was significantly higher in the CSU group (p=0,031, p<0,05). Patients with CIndU and CSU showed statistically similar responses to 2nd line treatments (combining or updosing AHs) (p=0,979; p>0,05). Twenty-seven (40,3%) of CIndU patients and 21 (31,8%) of CSU patients were diagnosed as AH-resistant urticaria. Omalizumab was administered to 15 CSU patients and 17 CIndU patients. Response rates to omalizumab were similar in both groups. Total response rates increased from 37,9% (n:25) to 68,2% (n:45) with the 2nd line treatments in CSU group while it increased from 20,9% (n:14) to 59,7% (n:40) in CIndU group. When omalizumab was introduced to AH-refractory cases as a 3rd line treatment, total response rates evaluated at the 12th week were 76,1% (n:51) in patients with CIndU and 83,3% (n:55) in CSU. Continuing omalizumab treatment for 24 weeks increased response rates in patients who were unresponsive at week 12.CIndU seem to be more resistant to standard doses of AHs and higher doses of AHs are required for the control of symptoms. The same guidelines for CSU may be implemented to patients with CIndU." @default.
- W2594418615 created "2017-03-16" @default.
- W2594418615 creator A5020473013 @default.
- W2594418615 creator A5025868485 @default.
- W2594418615 creator A5047373782 @default.
- W2594418615 creator A5056517863 @default.
- W2594418615 creator A5056695976 @default.
- W2594418615 creator A5071087836 @default.
- W2594418615 creator A5083741507 @default.
- W2594418615 date "2017-07-01" @default.
- W2594418615 modified "2023-10-18" @default.
- W2594418615 title "Management of chronic inducible urticaria according to the guidelines: A prospective controlled study" @default.
- W2594418615 cites W1558545064 @default.
- W2594418615 cites W1582795732 @default.
- W2594418615 cites W1594829213 @default.
- W2594418615 cites W1756057165 @default.
- W2594418615 cites W1867971684 @default.
- W2594418615 cites W1966770843 @default.
- W2594418615 cites W1968667225 @default.
- W2594418615 cites W1990534392 @default.
- W2594418615 cites W1992491010 @default.
- W2594418615 cites W1994733035 @default.
- W2594418615 cites W1999340483 @default.
- W2594418615 cites W2002752117 @default.
- W2594418615 cites W2022878537 @default.
- W2594418615 cites W2023246062 @default.
- W2594418615 cites W2027206303 @default.
- W2594418615 cites W2031640798 @default.
- W2594418615 cites W2037765836 @default.
- W2594418615 cites W2037982270 @default.
- W2594418615 cites W2048190537 @default.
- W2594418615 cites W2065333569 @default.
- W2594418615 cites W2069724741 @default.
- W2594418615 cites W2072799442 @default.
- W2594418615 cites W2076285395 @default.
- W2594418615 cites W2085255857 @default.
- W2594418615 cites W2090050388 @default.
- W2594418615 cites W2092431554 @default.
- W2594418615 cites W2102185544 @default.
- W2594418615 cites W2105700711 @default.
- W2594418615 cites W2108667284 @default.
- W2594418615 cites W2109951782 @default.
- W2594418615 cites W2121663010 @default.
- W2594418615 cites W2126299285 @default.
- W2594418615 cites W2126799517 @default.
- W2594418615 cites W2128371249 @default.
- W2594418615 cites W2129862555 @default.
- W2594418615 cites W2134995882 @default.
- W2594418615 cites W2146380285 @default.
- W2594418615 cites W2149120102 @default.
- W2594418615 cites W2149161476 @default.
- W2594418615 cites W2156152702 @default.
- W2594418615 cites W2263808315 @default.
- W2594418615 cites W2294084495 @default.
- W2594418615 cites W2305541861 @default.
- W2594418615 cites W2400798468 @default.
- W2594418615 cites W2411033312 @default.
- W2594418615 cites W2049702892 @default.
- W2594418615 doi "https://doi.org/10.1016/j.jdermsci.2017.02.283" @default.
- W2594418615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28314658" @default.
- W2594418615 hasPublicationYear "2017" @default.
- W2594418615 type Work @default.
- W2594418615 sameAs 2594418615 @default.
- W2594418615 citedByCount "31" @default.
- W2594418615 countsByYear W25944186152017 @default.
- W2594418615 countsByYear W25944186152018 @default.
- W2594418615 countsByYear W25944186152019 @default.
- W2594418615 countsByYear W25944186152020 @default.
- W2594418615 countsByYear W25944186152021 @default.
- W2594418615 countsByYear W25944186152022 @default.
- W2594418615 countsByYear W25944186152023 @default.
- W2594418615 crossrefType "journal-article" @default.
- W2594418615 hasAuthorship W2594418615A5020473013 @default.
- W2594418615 hasAuthorship W2594418615A5025868485 @default.
- W2594418615 hasAuthorship W2594418615A5047373782 @default.
- W2594418615 hasAuthorship W2594418615A5056517863 @default.
- W2594418615 hasAuthorship W2594418615A5056695976 @default.
- W2594418615 hasAuthorship W2594418615A5071087836 @default.
- W2594418615 hasAuthorship W2594418615A5083741507 @default.
- W2594418615 hasConcept C126322002 @default.
- W2594418615 hasConcept C141105273 @default.
- W2594418615 hasConcept C159110408 @default.
- W2594418615 hasConcept C159654299 @default.
- W2594418615 hasConcept C16005928 @default.
- W2594418615 hasConcept C188816634 @default.
- W2594418615 hasConcept C203014093 @default.
- W2594418615 hasConcept C207480886 @default.
- W2594418615 hasConcept C2776042228 @default.
- W2594418615 hasConcept C2778564945 @default.
- W2594418615 hasConcept C2779951463 @default.
- W2594418615 hasConcept C2994571964 @default.
- W2594418615 hasConcept C3017745231 @default.
- W2594418615 hasConcept C71924100 @default.
- W2594418615 hasConceptScore W2594418615C126322002 @default.
- W2594418615 hasConceptScore W2594418615C141105273 @default.
- W2594418615 hasConceptScore W2594418615C159110408 @default.
- W2594418615 hasConceptScore W2594418615C159654299 @default.
- W2594418615 hasConceptScore W2594418615C16005928 @default.